KSQ Therapeutics, Inc. logo

KSQ Therapeutics, Inc.

KSQ Therapeutics, is a drug discovery company employing cutting-edge functional genomics technology to identify novel pathways and targets involved in oncology and immuno-oncology.

KSQ was founded by David Sabatini from Whitehead Institute and MIT, William Hahn from Broad Institute and Dana-Farber Cancer Institute, Jonathan Weissman of UCSF and Tim Wang of MIT along with founding investors Flagship Pioneering and Polaris Partners.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://ksqtx.com
Founded2015
Disease Focus
Development Stage
STOCK CODENon Listed
Address
610 Main Street North 4th Floor,2139
Cambridge
United States
Email
Contact Number
+1 617-674-9150

KSQ Therapeutics, is a drug discovery company employing cutting-edge functional genomics technology to identify novel pathways and targets involved in oncology and immuno-oncology.

KSQ was founded by David Sabatini from Whitehead Institute and MIT, William Hahn from Broad Institute and Dana-Farber Cancer Institute, Jonathan Weissman of UCSF and Tim Wang of MIT along with founding investors Flagship Pioneering and Polaris Partners.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/ksq-therapeutics-inc-” connections=”true” suffix=””]

KSQ Therapeutics employs its proprietary CRISPRomics platform to identify novel pathways and targets involved in oncology and immuno-oncology and complete the functional assessment of each gene in more than 600 tumor and immune models. The company has compiled new insights in disease biology to identify novel drug targets and new drug combinations designed to elicit maximal impact on disease.

In Sep 2016, KSQ Therapeutics raised $76 Mn in a series A round led by Flagship Pioneering, with participation from Polaris Partners, ARCH Venture Partners, and Alexandria Equities.